Functional characterization of the novel antipsychotic iloperidone at human D2, D3, α2C, 5-HT6, and 5-HT1A receptors

Life Sciences

Volumn 73, Issue 9, 2003, Pages 1151-1159

  Kalkman, Hans O ^a   Feuerbach, Dominik ^a   Lötscher, Erika ^a   Schoeffter, Philippe ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Atypical antipsychotic; Iloperidone; Psychotic disorders; Schizophrenia

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2C ADRENERGIC RECEPTOR; CYCLIC AMP; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR STIMULATING AGENT; FORSKOLIN; ILOPERIDONE; NEUROLEPTIC AGENT; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN AGONIST;

ARTICLE; CELL LINE; CONCENTRATION RESPONSE; DRUG ACTIVITY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION;

EID: 0038682110     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(03)00419-3     Document Type: Article

References (38)

1. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 38:1999;1083-1152.
2. 2C-Adrenoceptor-overexpressing mice are impaired in executing non-spatial and spatial escape strategies. Molecular Pharmacology. 54:1998;569-576.
3. Boess F.G., Martin I.L. Molecular biology of 5-HT receptors. Neuropharmacology. 33:1994;275-317.
4. 3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochemistry International. 30:1997;565-574.
5. 3 receptor test in vitro predicts decreased cocaine self-administration in rats. Neuroreport. 8:1997;2373-2377.
6. Chen C., Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Molecular and Cellular Biology. 7:1987;2745-2752.
7. Corbett R., Griffiths L., Shipley J.E., Shukla U., Strupczewski J.T., Szczepanik A.M., Szewczak M.R., Turk D.J., Vargas H.M., Kongsamut S. Iloperidone: preclinical profile and early clinical evaluation. CNS Drug Reviews. 3:1997;120-147.
8. 2-noradrenergic system. Effects on cognition. Drugs and Aging. 5:1994;116-126.
9. Coull J.T., Frith C.D., Dolan R.J., Frackowiak R.S., Grasby P.M. The neural correlates of the noradrenergic modulation of human attention, arousal and learning. European Journal of Neuroscience. 9:1997;589-598.
10. 1A antagonist. British Journal of Pharmacology. 115:1995;1169-1174.
11. 2-adrenoceptor subtypes. Naunyn-Schmiedeberg's Archive of Pharmacology. 353:1996;391-399.
12. 1A receptor. Journal of Biological Chemistry. 264:1989;14848-14852.
13. 1A receptor antagonist. Behavioural Brain Research. 73:1996;337-353.
14. Francis P.T., Sims N.R., Procter A.W., Bowen D.M. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives. Journal of Neurochemistry. 60:1993;1589-1604.
15. Furchgott R.F. The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. Blaschko H., Muscholl E. Catecholamines. 1972;283-335 Springer, Berlin.
16. Goldman-Rakic P.S. The cortical dopamine system: role in memory and cognition. Advances in Pharmacology. 42:1998;707-711.
17. 2 receptor binding in patients with chronic schizophrenia. Psychopharmacology (Berl). 112:1993;S35-S39.
18. Jain K.K. An assessment of iloperidone for the treatment of schizophrenia. Expert Opinion on Investigational Drugs. 9:2000;2935-2943.
19. 2 receptors to neuronal circuits in human brain: insights into schizophrenia. Neuropsychopharmacology. 16:1997;375-384.
20. 2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs. European Journal of Pharmacology. 462:2003;33-40.
21. Kalkman H.O., Subramanian N., Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology. 25:2001;904-914.
22. 2-adrenoceptors. Journal of Psychopharmacology. 10(Suppl. 3):1996;2-5.
23. 6 serotonin receptor. Journal of Neurochemistry. 66:1996;47-56.
24. Kongsamut S., Roehr J.E., Cai J., Hartman H.B., Weissensee P., Kerman L.L., Tang L., Sandrasagra A. Iloperidone binding to human and rat dopamine and 5-HT receptors. European Journal of Pharmacology. 317:1996;417-423.
25. 2C-adrenergic receptor immunoreactivity in catecholaminergic neurons in the rat central nervous system. Neuroscience. 84:1998;1085-1096.
26. 3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacological Review. 49:1997;231-252.
27. Matkovits-Gupta T., Cucchiaro J., El-Bizri H., Fairweather D., Klonowski E., Lasser R., Nann-Vernotica E., Narurka M., Pirrozi C., Waltrip R., Young F., Gharabawi G. Safety and efficacy of iloperidone in patients with psychotic disorders. Schizophrenia Research. 49:2001;238.
28. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 21(Suppl. 2):1999;106S-115S.
29. 2-autoreceptor-mediated modulation of tyrosine hydroxylase activity in noradrenergic regions of the brain in vivo. Naunyn-Schmiedebergs Archives of Pharmacology. 345:1992;653-660.
30. 3 receptor agonist. Nature. 400:1999;371-375.
31. Richelson E., Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sciences. 68:2000;29-39.
32. 3H]cAMP in cell monolayers, cell suspensions, and tissue slices. Methods in Enzymology. 195:1991;22-28.
33. Scatton B., Zivkovic B., Dedek J. Antidopaminergic properties of yohimbine. Journal of Pharmacology and Experimental Therapeutics. 215:1980;494-499.
34. 1A receptors: considerations on receptor effector coupling across systems. Neuropharmacology. 36:1997;429-437.
35. 3 dopamine receptor in cellular and organismal function. Psychopharmacology (Berl). 135:1998;1-16.
36. Sokoloff P., Schwartz J.C. Novel dopamine receptors half a decade later. Trends in Pharmacological Sciences. 16:1995;270-275.
37. 3 receptor antagonist with high oral bioavailability and CNS penetration in the rat. Journal of Medicinal Chemistry. 43:2000;1878-1885.
38. 3 receptors. European Journal of Pharmacology. 424:2001;85-90.